194 related articles for article (PubMed ID: 34895696)
41. Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy.
Acharya UH; Dhawale T; Yun S; Jacobson CA; Chavez JC; Ramos JD; Appelbaum J; Maloney DG
Expert Rev Hematol; 2019 Mar; 12(3):195-205. PubMed ID: 30793644
[TBL] [Abstract][Full Text] [Related]
42. 2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.
Li P; Liu Y; Liang Y; Bo J; Gao S; Hu Y; Hu Y; Huang H; Huang X; Jing H; Ke X; Li J; Li Y; Liu Q; Lu P; Mei H; Niu T; Song Y; Song Y; Su L; Tu S; Wang J; Wu D; Wang Z; Xu K; Ying Z; Yang Q; Zhang Y; Shi F; Zhang B; Zhang H; Zhang X; Zhao M; Zhao W; Zhao X; Huang L; Zhu J; Qian W; Han W; Liang A
Cancer Biol Med; 2023 Mar; 20(2):129-46. PubMed ID: 36861439
[TBL] [Abstract][Full Text] [Related]
43. Associations of granulocyte colony-stimulating factor with toxicities and efficacy of chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma.
Ma S; Li H; Zhou D; Zhang X; Shi M; Cao J; Qi Y; Xia J; Liu Y; Wang X; Li D; Sang W; Yan Z; Zhu F; Sun H; Cheng H; Zheng J; Xu K; Li Z; Qi K; Wang Y
Cytotherapy; 2023 Jun; 25(6):653-658. PubMed ID: 36907717
[TBL] [Abstract][Full Text] [Related]
44. Case Report: Local Cytokine Release Syndrome in an Acute Lymphoblastic Leukemia Patient After Treatment With Chimeric Antigen Receptor T-Cell Therapy: A Possible Model, Literature Review and Perspective.
Luan C; Zhou J; Wang H; Ma X; Long Z; Cheng X; Chen X; Huang Z; Zhang D; Xia R; Ge J
Front Immunol; 2021; 12():707191. PubMed ID: 34349766
[TBL] [Abstract][Full Text] [Related]
45. Clinical units to set up chimeric antigen receptor T-cell therapy (CAR T-cells): Based on the recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC).
Yakoub-Agha I
Curr Res Transl Med; 2018 May; 66(2):57-58. PubMed ID: 29685843
[TBL] [Abstract][Full Text] [Related]
46. Toxicities of CD19 CAR-T cell immunotherapy.
Hirayama AV; Turtle CJ
Am J Hematol; 2019 May; 94(S1):S42-S49. PubMed ID: 30784102
[TBL] [Abstract][Full Text] [Related]
47. Cellular therapy: Immune-related complications.
Oved JH; Barrett DM; Teachey DT
Immunol Rev; 2019 Jul; 290(1):114-126. PubMed ID: 31355491
[TBL] [Abstract][Full Text] [Related]
48. Management of Chimeric Antigen Receptor (CAR) T-Cell Toxicities: A Review and Guideline for Emergency Providers.
Gupta R; Roach C; Hryniewicki AT; Vilke GM; Shatsky RA; Coyne CJ
J Emerg Med; 2020 Jul; 59(1):61-74. PubMed ID: 32473867
[TBL] [Abstract][Full Text] [Related]
49. Potential Role of IFNγ Inhibition in Refractory Cytokine Release Syndrome Associated with CAR T-cell Therapy.
McNerney KO; DiNofia AM; Teachey DT; Grupp SA; Maude SL
Blood Cancer Discov; 2022 Mar; 3(2):90-94. PubMed ID: 35015687
[TBL] [Abstract][Full Text] [Related]
50. Cardiovascular Toxicities with Chimeric Antigen Receptor T-cell Therapy.
Gill J
Curr Cardiol Rev; 2023; 19(1):e230622206353. PubMed ID: 35747980
[TBL] [Abstract][Full Text] [Related]
51. Recognizing, defining, and managing CAR-T hematologic toxicities.
Rejeski K; Subklewe M; Locke FL
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):198-208. PubMed ID: 38066881
[TBL] [Abstract][Full Text] [Related]
52. Building safety into CAR-T therapy.
Peters DT; Savoldo B; Grover NS
Hum Vaccin Immunother; 2023 Dec; 19(3):2275457. PubMed ID: 37968136
[TBL] [Abstract][Full Text] [Related]
53. Increased visceral fat distribution and body composition impact cytokine release syndrome onset and severity after CD19 chimeric antigen receptor T-cell therapy in advanced B-cell malignancies.
Dos Santos DMC; Rejeski K; Winkelmann M; Liu L; Trinkner P; Günther S; Bücklein VL; Blumenberg V; Schmidt C; Kunz WG; Von Bergwelt-Baildon M; Theurich S; Subklewe M
Haematologica; 2022 Sep; 107(9):2096-2107. PubMed ID: 35172565
[TBL] [Abstract][Full Text] [Related]
54. Individual Patient Data Meta-Analysis from 16 Trials for Safety Factors in Cytokine Release Syndrome After CAR-T Therapy in Patients with Non-Hodgkin Lymphoma (NHL) and Acute Lymphoblastic Leukemia.
Li J; Wu Z; Zhao N
Adv Ther; 2019 Oct; 36(10):2881-2894. PubMed ID: 31428935
[TBL] [Abstract][Full Text] [Related]
55. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
56. Toci or not toci: innovations in the diagnosis, prevention, and early management of cytokine release syndrome.
Banerjee R; Fakhri B; Shah N
Leuk Lymphoma; 2021 Nov; 62(11):2600-2611. PubMed ID: 34151714
[TBL] [Abstract][Full Text] [Related]
57. Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial.
Kadauke S; Myers RM; Li Y; Aplenc R; Baniewicz D; Barrett DM; Barz Leahy A; Callahan C; Dolan JG; Fitzgerald JC; Gladney W; Lacey SF; Liu H; Maude SL; McGuire R; Motley LS; Teachey DT; Wertheim GB; Wray L; DiNofia AM; Grupp SA
J Clin Oncol; 2021 Mar; 39(8):920-930. PubMed ID: 33417474
[TBL] [Abstract][Full Text] [Related]
58. Introducing innovative cellular therapies into the clinic: a 2-year retrospective experience of a chimeric antigen receptor T-cell programme at a single centre in Switzerland.
Stolz S; Roncador M; Rösler W; Zenz T; Manz MG; Müller AMS; Widmer CC
Swiss Med Wkly; 2022 Jun; 152():w30186. PubMed ID: 35752964
[TBL] [Abstract][Full Text] [Related]
59. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
Ernst M; Oeser A; Besiroglu B; Caro-Valenzuela J; Abd El Aziz M; Monsef I; Borchmann P; Estcourt LJ; Skoetz N; Goldkuhle M
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013365. PubMed ID: 34515338
[TBL] [Abstract][Full Text] [Related]
60. Predictive role of endothelial cell activation in cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukaemia.
Hong F; Shi M; Cao J; Wang Y; Gong Y; Gao H; Li Z; Zheng J; Zeng L; He A; Xu K
J Cell Mol Med; 2021 Dec; 25(24):11063-11074. PubMed ID: 34734474
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]